Many drugs targeting CTLA-4/PD-1 have been approved for the treatment of different types of cancers, including melanoma, lung, breast, bladder, and gastric cancer, classic Hodgkin’s lymphoma, and B-cell lymphoma [51]. This evidence concerns the gene CTLA4 and Hodgkins lymphoma.